

# A Matter of Attention

## Inconsistencies between prescriptions and drug intake in elderly multimorbid patients in primary care

**C. Muth<sup>1</sup>, M. Beyer<sup>1</sup>, K. Zint<sup>2</sup>, M. Ganso<sup>1</sup>,  
K. Saal<sup>1</sup>, F.M. Gerlach<sup>1</sup>, W.E. Haefeli<sup>2</sup>**

<sup>1</sup> Institute for General Practice, Goethe-University, Frankfurt am Main

<sup>2</sup> Dept. of Internal Medicine IV, Clinical Pharmacology and Pharmacoepidemiology,  
University Hospital Heidelberg



*EGPRN is a network organisation within  
WONCA Region Europa - ESGP/FM*

**Budapest, 17.10.2008**



Grant # 01GK0302



Pre-publication of preliminary data - do not cite!

## Topics

- Study: cross sectional study in 20 GPs to detect inappropriate medications in elderly multimorbid patients
- Research question: prevalence of inconsistencies between drug prescription and intake
- Material and methods
- Results:
  - prescriptions not filled in (non-adherence)
  - additional medications of the patient (OTC etc.)
  - differences in dosage / dosing intervals
- Further results (may be discussed):
  - adjustment of dosage in renal impairment
  - (risk of) interaction
  - inappropriate medications in the elderly ('Beers list')
- Discussion and conclusions

Pre-publication of preliminary data - do not cite!

## Multimorbidity, age, and polypharmacy



- Increasing age, multimorbidity and polypharmacy ► increasing risk of inappropriate prescriptions [1-3]
- Inappropriate prescriptions ► predictor for (preventable?) adverse drug events (ADE), particularly in the elderly [4-6]

[1] Glaeske G, Janhsen K (2007) GEK-Arzneimittel-Report 2007

[2] Steinman MA, et al. (2006) J Am Geriatr Soc 54(10):1516-23

[3] Fialová D, et al. (2005) JAMA 293(11):1348-58

[4] Field TS, et al. (2004) J Am Geriatr Soc 52(8):1349-54

[5] Kuijpers MAJ, et al. & The OLDY (Old people Drugs & dYsregulations) study group (2007) Br J Clin Pharmacol 65(1):130-3

[6] Leendertse AJ, et al. (2008) Arch Int Med 168(17): 1890-6

Pre-publication of preliminary data - do not cite!

## Setting and design

Cross-sectional study in 20 family practices (convenience sample)

### Family practices:

List of the 50 'most expensive' patients  
≥ age 65  
≥3 diagn.  
≥5 medic. capable for interview

### Institute:

randomized sample  
15 pat./pract.

### Family pract. :

inclusion of 10 consec. patients after *informed consent*

**GPs:** Documentation of current medication (and indication!), sociodemographic data, diagnoses and comorbidity

### Institute:

- structured telephone interview with the patients (drug identification code)

Pre-publication of preliminary data - do not cite!

## Methods: Comparisons

### GP documentation → Patient interview:

- prescriptions only found in GP documentation (exactly // same agent [ATC])
- Dosage in prescription *higher* than taken
- Dosage in prescription *lower* than taken
- Differences in intake scheme

### Patient interview → GP documentation:


- Drugs presented only by the patient
- Use of drugs 'to be taken as needed'



Pre-publication of preliminary data - do not cite!

## Results I

- **17/21** practices did participate
- **169\*** patients:
  - male 49.7 %
  - age (median) 74y
  - drugs / pat. (median) 8 (5-16)
  - (long term) diagnoses 11 (4-33)
  - CIRS (median) 10 (1-26)



\* data reviewed, compared to the abstract!

Pre-publication of preliminary data - do not cite!

## Results II: Prescription vs. actual intake (total)

- Differences in GP documentation vs. patient interview:  
**151/169 Patients (89.3 %)**  
**Per patient: median 3 (0 to 13 differences)**
- Differences in patient interview vs. GP documentation:  
**119/160 Patients (74.4 %)**  
**Per patient: median 2 (0 bis 26 differences)**
- **At least one mismatch: in 96.1 % (!) of the patients**



Pre-publication of preliminary data - do not cite!

## Results III: Prescription vs. actual intake

Prescriptions *only* found in GP documentation, *not* in patient interview: n=240 prescr. (70.0 % pat.)

Prescriptions higher dosed by the GP: n=105 prescr. (46.3 % pat.)

Prescriptions lower dosed by the GP: n=103 prescr. (41.3 % pat.)

Interview_reg								Medikamente_reg							
Pat_ID: 0102								Pat_ID: 0102							
Handelsname:	Dosierung		ordner		ATC	Vergleich		Handelsname:	Dosierung		ATC		Vergleich		
Aromasin 25	1	0	0	0	HA	L02BG06	0	Aromasin 25mg	1	0	0	0	L02BG06		
ASS 100	1	0	0	0	HA	B01AC06	0	ASS 100	1	0	0	0	B01AC06		
L-Thyroxin 75 mg	1	0	0	0	HA	H03AA01	0	Euthyrox 75 µg	1	0	0	0	H03AA01		
Lyrica 150	1	0	1	0	HA	N03AX16	0	Lyrica 75mg	1	1	0	0	N03AX16	4	
Lyrica 25	2	0	2	0	HA	N03AX16	0	Ramipril 2,5 m					C09AA05		
Lyrica 75	1	0	1	0	HA	N03AX16	0								
Ramipril						C09AA05	0								

550 mg  
Pregabalin

150 mg  
Pregabalin



Pre-publication of preliminary data - do not cite!

## Results IV: Prescription vs. actual intake (II)

Differences in the *usage scheme* (may be relevant e.g. corticoids in asthma): n=127 prescr. (43.2% pat.)

Medications (drug use) *only mentioned by the patient*: n=306 drugs (72.5% pat.)

Interview_reg								Medikamente_reg							
Pat_ID: 0905								Pat_ID: 0905							
Handelsname:	Dosierung			Verordner		ATC	Vergleich	Handelsname:	Dosierung			ATC		Vergleich	
Allopurinol 300	0,5	0	0	0	HA	M04AA01		Allopurinol AL 100	1	0	0	0	M04AA01	2	
Chloraldurat	0	0	0	1	HA	N05CC01		Calcium D3	1	0	0	0	A12AX01		
Ezetrol	1	0	0	0	HA	C10AX09		Chloraldurat rot	0	0	0	1	N05CC01		
Foradil	1	0	1	0	FA	R03AC13	1	Ezetrol 10mg	0	0	1	0	C10AX09		
Formotop	1	0	0	0	HA	R03AC13		Formotop 12 UG	1	0	1	0	R03AC13		
Lisinopril 5 mg	0	0	1	0	HA	C09AA03		Lisi Puvon 5 mg	0,5	0	0	0	C09AA03	4	
Marcumar	0	0	0	0	HA	B01AA04	1	Molsidomin 8 ret	0	0	1	0	C01DX12		
Molsidomin 6 mg	0	0	1	0	HA	C01DX12		Oxazepam 10 mg	0	0	0	1	N05BA04	2	
Oxazepam 50 mg	0	0	0	0	HA	N05BA04		Pentalong 80 mg	1	0	1	0	C01DA05	3	
Pentalon 80 mg	1	0	0	0	HA	C01DA05		Sortis 40 mg	0	0	0,5	0	C10AA05	2	
Spiriva	1	0	1	0	FA	R03B804									
Torem 10 mg	1	0	0	0	HA	C03CA04									

Pre-publication of preliminary data - do not cite!  
**Frequency by agents (ATC groups):**

Drugs differently taken by the patient (>2 %; n=357/1467)			Differences in prescription (>2 %; n=589/1471)		
	ATC	%		ATC	%
Minerals	A12	12		Diuretics	C03 8,6
Nutritionals	A99	6,7		Antidiabetics	A10 7,1
Sympathomimetics etc.	R03	6,7		ACE-Inhibit.	C09 7
Antiphlogist./NSAR	M01	5,2		Betablockers	C07 6,8
Cardiacs (incl. Antiarr.)	C01	4,3		Sympathomimetica etc.	R03 6,6
Analgetics	N02	4		Lipid lowering drugs	C10 6,1
Diuretics	C03	3,7		Antacida	A02 5,5
Psycholeptica	N05	3,7		Cardiacs (incl. Antiarr.)	C01 4,6
Antidiabetics	A10	3,4		Analgetics	N02 4,6
Antidepressants	N06	3,4		Gout	M04 3,9
Ophthalmica	S01	3,4		Minerals	A12 3,8
Urologics	G04	3,1		Antithrombot.agents	B01 3,8
Vitamins	A11	2,8		Antidepressants	N06 3,4
Antacida	A02	2,4		Antiphlogist./NSAR	M01 2,9
Ca-Antagonisten	C08	2,4		Ca-Antagonists	C08 2,7
Antithrombot. agents	B01	2,1		Psycholeptica	N05 2
Sum		70		Sum	79
Others		31		Others	21

Pre-publication of preliminary data - do not cite!

## Results V: Prescription vs. actual intake (III)

### An urgent problem: 'Drugs to be taken as needed'...

(these are only the 'drugs as needed' - not the regular medication he receives...)

Interview_bedarf				
Pat_ID:	0515			
Handelsname:	Dosierung:	Verordner	ATC	Vergleich
Adalat 10	bei Bedarf	KH	C08CA05	5
Diazepam	bei Bedarf	HA	N05BA01	5
Gingko D2	gelegentlich	HA	C04AH01	1
Nitro	bei Bedarf	KH	C01DA02	5
Nitrolingual	bei Bedarf	KH	C01DA02	5
Omeprazol	bei Bedarf	HA	A02BC01	5
Tavor	bei Bedarf	HA	N05BA06	5

Medikamente_bed					
Pat_ID:	0515				
Handelsname:	Dosierung	Einzel-dosis - max	Gesamt	ATC	Vergleich:
Adalat 10mg	0	1		C08CA05	
Diazepam 10mg	0	1		N05BA01	
Nitro Kap.	0	1		C01DA02	
Nitrolingual Spray	0	2 Hub		C01DA02	
Omeprazol 40mg	0	1		A02BC01	
Tavor 10mg	0	1		N05BA06	

This is a patient 78 y of age. Will he know appropriately *when to use* nifedipine, nitro, and particularly the benzodiazepine (Tavor)?

**Besides:** Is the GP conscious that the patient has two benzodiazepines at his hand at the same time?

Pre-publication of preliminary data - do not cite!

## Limitations of our study

- **Rather small, convenience sample (on practice level)**
- **Reporting bias in the patient interview :**
  - exceptional situation: the University Hospital Frankfurt calls up
  - medications not available at the moment,
  - misunderstanding during the interview (insuline is not yet a pill..)
- **Time lag:** mean lag between documentation and interview was 31 days, (in single cases up to 102 days)
- **Cognitive fitness could not be tested**
- **Physicians' difficulties to determine the 'actual medication'**

Pre-publication of preliminary data - do not cite!

## Further results

The study was intended to determine inappropriate medications in the elderly in different respects. In the meantime we can present additional findings.

- **Inappropriate dosages in renal impairment** were found in 23 % of the patients.
- In 25% of the patients, a **clinical relevant risk of drug interaction** was found.
- 39.1 % of the patients got a prescription, which is **'potentially inappropriate in the elderly'** (Beers list).
- We found relevant contraindications against at least one prescribed drug in 14.8 % of the patients.
- **-> A lot of drug safety problems of polypharmacy in the elderly**

Pre-publication of preliminary data - do not cite!

## Conclusions

- **A starting point in any strategy to improve the safety of polypharmacy in the elderly consists in knowing exactly, what the patient actually takes.** Main impediments are
  - Deficits in documentation,
  - Prescriptions by other physicians, and
  - The patient's own decisions
- Regularly, a **medication reconciliation** should take place.
- We need further knowledge about **crucial problems in the polypharmacy in the elderly** - targeted on individual conditions.



Pre-publication of preliminary data - do not cite!


**Thank you!**

**Special acknowledgement  
to Tatjana Blazejewski (data  
handling / query management)  
and Agnes Fink (interviews)**



Pre-publication of preliminary data - do not cite!


# Adjustment in renal impairment (RI)





Pre-publication of preliminary data - do not cite!

## Drug interactions



Pre-publication of preliminary data - do not cite!

## Beers-criteria (Beers 1997 & Fick 2003)

